Lantern Pharma Inc.
LTRNNasdaq
$2.87
↓ -1.4%Jul 17 close · end-of-day
Price
1Y↓ -28.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$32.3M
Enterprise Value
$26.0M
P/E
—
P/S
—
P/B
9.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$15.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-461.8%
ROIC
—
Debt / Equity
—
Net Cash
$6.3M
Return 1Y
-32.9%
Company profile
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
- CEO
- Panna L. Sharma
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Texas
- Website
- lanternpharma.com
Earnings
LTRN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.30↓ -28.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | -$12.6M | -$14.4M | -$17.9M | -$22.2M | -$18.0M |
| Net income | -$5.9M | -$12.4M | -$14.3M | -$16.0M | -$20.8M | -$17.1M |
| Diluted EPS | — | — | -$1.31 | -$1.47 | -$1.93 | -$1.57 |
| Operating cash flow | -$5.7M | -$10.6M | -$12.8M | -$14.3M | -$17.8M | -$15.7M |
| Free cash flow | — | -$10.6M | -$12.8M | -$14.4M | -$17.8M | -$15.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.4M | -$5.2M | -$5.9M | -$4.8M | -$4.7M | -$4.3M | -$4.2M | -$3.4M |
| Net income | -$5.0M | -$4.5M | -$5.9M | -$4.5M | -$4.3M | -$4.2M | -$4.1M | -$3.3M |
| Diluted EPS | -$0.46 | -$0.42 | -$0.54 | -$0.42 | -$0.40 | -$0.39 | -$0.36 | -$0.30 |
| Operating cash flow | -$5.2M | -$5.6M | -$4.0M | -$4.4M | -$3.9M | -$4.6M | -$2.8M | -$3.8M |
| Free cash flow | -$5.2M | -$5.6M | -$4.0M | -$4.4M | -$3.9M | -$4.6M | -$2.8M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-12 | Schalop Lee Troy | Buy | 48,544 | $2.06 | $100,000.64 | filing |
| 2026-05-12 | KEYSER D JEFFREY | Buy | 48,544 | $2.06 | $100,000.64 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.